Dimethyl fumarate Teva Unjoni Ewropea - Malti - EMA (European Medicines Agency)

dimethyl fumarate teva

teva gmbh - dimetil fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressanti - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Tecfidera Unjoni Ewropea - Malti - EMA (European Medicines Agency)

tecfidera

biogen netherlands b.v. - dimetil fumarate - sklerosi multipla - immunosoppressanti - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Dimethyl fumarate Mylan Unjoni Ewropea - Malti - EMA (European Medicines Agency)

dimethyl fumarate mylan

mylan ireland limited - dimetil fumarate - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosoppressanti - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Polpharma Unjoni Ewropea - Malti - EMA (European Medicines Agency)

dimethyl fumarate polpharma

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetil fumarate - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosoppressanti - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Accord Unjoni Ewropea - Malti - EMA (European Medicines Agency)

dimethyl fumarate accord

accord healthcare s.l.u. - dimetil fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressanti - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Okedi Unjoni Ewropea - Malti - EMA (European Medicines Agency)

okedi

laboratorios farmacéuticos rovi, s.a. - risperidone - skizofrenija - psikolettiċi - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Mayzent Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mayzent

novartis europharm limited  - siponimod-aċidu fumariku - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosuppressanti selettivi - mayzent huwa indikat għall-kura ta ' pazjenti adulti bi sklerożi multipla progressiva sekondarja (spms), bil-marda attiva muri mill-irkadar jew l-immaġini tal-karatteristiċi ta'l-attività infjammatorja.

Gardasil 9 Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gardasil 9

merck sharp & dohme b.v. - vaċċin tal-papillomavirus uman [tipi 6, 11, 16, 18, 31, 33, 45, 52, 58] (rikombinanti, assorbjati) - condylomata acuminata; papillomavirus infections; immunization; uterine cervical dysplasia - vaċċini għal papillomavirus - gardasil 9 huwa indikat għall-immunizzazzjoni attiva ta 'l-individwi mill-età ta'9 snin kontra l-hpv-mard:premalignant leżjonijiet u l-kanċer li jaffettwa l-ċerviċi, vulva, tal-vaġina u l-anus ikkawżat minn hpv ta' vaċċin typesgenital-felul (kondiloma acuminata) ikkawżata mill-speċifiċi tipi ta ' hpv. ara t-taqsimiet 4. 4 u 5. 1 għal tagħrif importanti dwar l-informazzjoni li ssostni dawn l-indikazzjonijiet. l-użu ta ' gardasil 9 għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Macugen Unjoni Ewropea - Malti - EMA (European Medicines Agency)

macugen

pharmaswiss ceska republika s.r.o - pegaptanib - deġenerazzjoni makulari mxarrba - oftalmoloġiċi - macugen huwa indikat għat-trattament ta 'deġenerazzjoni makulari neovaskulari (mxarrba) relatata ma' l-età (amd).

Suliqua Unjoni Ewropea - Malti - EMA (European Medicines Agency)

suliqua

sanofi winthrop industrie - l-insulina glargine, lixisenatide - diabetes mellitus, tip 2 - drogi użati fid-dijabete - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.